Knight Therapeutics Stock Investor Sentiment

GUD Stock  CAD 6.27  0.02  0.32%   
About 53% of Knight Therapeutics' investor base is interested to short. The analysis of the overall prospects from investing in Knight Therapeutics suggests that many traders are, at the present time, impartial. Knight Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Knight Therapeutics. Many technical investors use Knight Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
18 hours ago at news.google.com         
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results - GlobeNewswire
Google News at Macroaxis
a day ago at news.google.com         
Technical Patterns and Signals - Stock Traders Daily
Google News at Macroaxis
3 days ago at news.google.com         
Knight Therapeutics wins target raise at RBC - Cantech Letter
Google News at Macroaxis
over a week ago at news.google.com         
Strategic Acquisition Boosts Knight Therapeutics Analyst Recommends Buy - TipRanks
Google News at Macroaxis
over a week ago at news.google.com         
Knight Therapeutics to Acquire Paladin - Yahoo Finance
Google News at Macroaxis
over two weeks ago at news.google.com         
On The My Stocks Page - Stock Traders Daily
Google News at Macroaxis
over two weeks ago at news.google.com         
Stock Analysis and Trading Signals - Stock Traders Daily
Google News at Macroaxis
over three weeks ago at news.google.com         
Proactive Strategies - Stock Traders Daily
Google News at Macroaxis
over a month ago at news.google.com         
Technical Patterns and Signals - Stock Traders Daily
Google News at Macroaxis
over a month ago at news.google.com         
Knight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, ...
Google News at Macroaxis
over a month ago at news.google.com         
Knight Therapeutics Shares Down 0.2 percent - Whats Next - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Knight Therapeutics Inc. most popular amongst individual investors who own 41 percent of the shares,...
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree in Canada - GlobeNewswire
Google News at Macroaxis
over three months ago at news.google.com         
Closing Bell Knight Therapeutics Inc Up On Thursday - Barchart
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Inc. Insider Sime Armoyan Buys 90,300 Shares - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Knight Therapeutics that are available to investors today. That information is available publicly through Knight media outlets and privately through word of mouth or via Knight internal channels. However, regardless of the origin, that massive amount of Knight data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Knight Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Knight Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Knight Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Knight Therapeutics alpha.

Knight Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Knight Therapeutics Shares Down 0.2 percent - Whats Next - MarketBeat
01/27/2025
2
Proactive Strategies - Stock Traders Daily
02/19/2025
3
Knight Therapeutics to Acquire Paladin - Yahoo Finance
03/11/2025
4
Technical Patterns and Signals - Stock Traders Daily
03/19/2025

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.